Sinthu Pathmanapan1,2, Olga Ilkayeva3,4, John T Martin5, Adrian Kwan Ho Loe1, Hongyuan Zhang5, Guo-Fang Zhang4, Christopher B Newgard3,4, Jay S Wunder6, Benjamin A Alman7. 1. Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto, ON, Canada. 2. Institute of Medical Science, University of Toronto, Toronto, ON, Canada. 3. Department of Pharmacology & Cancer Biology, Duke University, Durham, NC, USA. 4. Sarah W. Stedman Nutrition and Metabolism Center and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA. 5. Department of Orthopaedic Surgery, Duke University, 311 Trent, Durham, NC, 27710, USA. 6. Lunenfeld-Tanenbaum Research Institute, and the University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, ON, Canada. 7. Department of Orthopaedic Surgery, Duke University, 311 Trent, Durham, NC, 27710, USA. ben.alman@duke.edu.
Abstract
BACKGROUND: Majority of chondrosarcomas are associated with a number of genetic alterations, including somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes, but the downstream effects of these mutated enzymes on cellular metabolism and tumor energetics are unknown. As IDH mutations are likely to be involved in malignant transformation of chondrosarcomas, we aimed to exploit metabolomic changes in IDH mutant and non-mutant chondrosarcomas. METHODS: Here, we profiled over 69 metabolites in 17 patient-derived xenografts by targeted mass spectrometry to determine if metabolomic differences exist in mutant IDH1, mutant IDH2, and non-mutant chondrosarcomas. UMAP (Uniform Manifold Approximation and Projection) analysis was performed on our dataset to examine potential similarities that may exist between each chondrosarcoma based on genotype. RESULTS: UMAP revealed that mutant IDH chondrosarcomas possess a distinct metabolic profile compared with non-mutant chondrosarcomas. More specifically, our targeted metabolomics study revealed large-scale differences in organic acid intermediates of the tricarboxylic acid (TCA) cycle, amino acids, and specific acylcarnitines in chondrosarcomas. Lactate and late TCA cycle intermediates were elevated in mutant IDH chondrosarcomas, suggestive of increased glycolytic metabolism and possible anaplerotic influx to the TCA cycle. A broad elevation of amino acids was found in mutant IDH chondrosarcomas. A few acylcarnitines of varying carbon chain lengths were also elevated in mutant IDH chondrosarcomas, but with minimal clustering in accordance with tumor genotype. Analysis of previously published gene expression profiling revealed increased expression of several metabolism genes in mutant IDH chondrosarcomas, which also correlated to patient survival. CONCLUSIONS: Overall, our findings suggest that IDH mutations induce global metabolic changes in chondrosarcomas and shed light on deranged metabolic pathways.
BACKGROUND: Majority of chondrosarcomas are associated with a number of genetic alterations, including somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes, but the downstream effects of these mutated enzymes on cellular metabolism and tumor energetics are unknown. As IDH mutations are likely to be involved in malignant transformation of chondrosarcomas, we aimed to exploit metabolomic changes in IDH mutant and non-mutant chondrosarcomas. METHODS: Here, we profiled over 69 metabolites in 17 patient-derived xenografts by targeted mass spectrometry to determine if metabolomic differences exist in mutant IDH1, mutant IDH2, and non-mutant chondrosarcomas. UMAP (Uniform Manifold Approximation and Projection) analysis was performed on our dataset to examine potential similarities that may exist between each chondrosarcoma based on genotype. RESULTS:UMAP revealed that mutant IDH chondrosarcomas possess a distinct metabolic profile compared with non-mutant chondrosarcomas. More specifically, our targeted metabolomics study revealed large-scale differences in organic acid intermediates of the tricarboxylic acid (TCA) cycle, amino acids, and specific acylcarnitines in chondrosarcomas. Lactate and late TCA cycle intermediates were elevated in mutant IDH chondrosarcomas, suggestive of increased glycolytic metabolism and possible anaplerotic influx to the TCA cycle. A broad elevation of amino acids was found in mutant IDH chondrosarcomas. A few acylcarnitines of varying carbon chain lengths were also elevated in mutant IDH chondrosarcomas, but with minimal clustering in accordance with tumor genotype. Analysis of previously published gene expression profiling revealed increased expression of several metabolism genes in mutant IDH chondrosarcomas, which also correlated to patient survival. CONCLUSIONS: Overall, our findings suggest that IDH mutations induce global metabolic changes in chondrosarcomas and shed light on deranged metabolic pathways.
Authors: Chendong Yang; Bookyung Ko; Christopher T Hensley; Lei Jiang; Ajla T Wasti; Jiyeon Kim; Jessica Sudderth; Maria Antonietta Calvaruso; Lloyd Lumata; Matthew Mitsche; Jared Rutter; Matthew E Merritt; Ralph J DeBerardinis Journal: Mol Cell Date: 2014-10-21 Impact factor: 17.970
Authors: Christian M Metallo; Paulo A Gameiro; Eric L Bell; Katherine R Mattaini; Juanjuan Yang; Karsten Hiller; Christopher M Jewell; Zachary R Johnson; Darrell J Irvine; Leonard Guarente; Joanne K Kelleher; Matthew G Vander Heiden; Othon Iliopoulos; Gregory Stephanopoulos Journal: Nature Date: 2011-11-20 Impact factor: 49.962
Authors: Mette V Jensen; Jamie W Joseph; Olga Ilkayeva; Shawn Burgess; Danhong Lu; Sarah M Ronnebaum; Matthew Odegaard; Thomas C Becker; A Dean Sherry; Christopher B Newgard Journal: J Biol Chem Date: 2006-06-01 Impact factor: 5.157
Authors: Guo Gord Zhu; Khedoudja Nafa; Narasimhan Agaram; Ahmet Zehir; Ryma Benayed; Justyna Sadowska; Laetitia Borsu; Ciara Kelly; William D Tap; Nicola Fabbri; Edward Athanasian; Patrick J Boland; John H Healey; Michael F Berger; Marc Ladanyi; Meera Hameed Journal: Clin Cancer Res Date: 2019-10-15 Impact factor: 13.801
Authors: Darrell R Borger; Lipika Goyal; Thomas Yau; Ronnie T Poon; Marek Ancukiewicz; Vikram Deshpande; David C Christiani; Hannah M Liebman; Hua Yang; Hyeryun Kim; Katharine Yen; Jason E Faris; A John Iafrate; Eunice L Kwak; Jeffrey W Clark; Jill N Allen; Lawrence S Blaszkowsky; Janet E Murphy; Supriya K Saha; Theodore S Hong; Jennifer Y Wo; Cristina R Ferrone; Kenneth K Tanabe; Nabeel Bardeesy; Kimberly S Straley; Sam Agresta; David P Schenkein; Leif W Ellisen; David P Ryan; Andrew X Zhu Journal: Clin Cancer Res Date: 2014-01-29 Impact factor: 13.801
Authors: Peter Van Loo; Adrienne M Flanagan; William Cross; Iben Lyskjær; Tom Lesluyes; Steven Hargreaves; Anna-Christina Strobl; Christopher Davies; Sara Waise; Shadi Hames-Fathi; Dahmane Oukrif; Hongtao Ye; Fernanda Amary; Roberto Tirabosco; Craig Gerrand; Toby Baker; David Barnes; Christopher Steele; Ludmil Alexandrov; Gareth Bond; Paul Cool; Nischalan Pillay Journal: Genome Med Date: 2022-08-30 Impact factor: 15.266
Authors: Hongyuan Zhang; Vijitha Puviindran; Puviindran Nadesan; Xiruo Ding; Leyao Shen; Yuning J Tang; Hidetoshi Tsushima; Yasuhito Yahara; Ga I Ban; Guo-Fang Zhang; Courtney M Karner; Benjamin A Alman Journal: J Bone Miner Res Date: 2022-03-22 Impact factor: 6.390